The nation of Zimbabwe has rejected a significant American health deal valued at 367 million US dollars (272 million pounds) over five years due to Washington's request for confidential information.
This move came to light after a internal memorandum from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government representative later clarified that the United States was requesting genetic material for research and commercial purposes while was not willing to share the benefits from future vaccines.
"We must now begin the challenging and unfortunate process of scaling back our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had furnished more than $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for continued negotiations to find a agreement suitable to both sides so the country's vital HIV treatment initiative can continue.
Wider Background
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a high court suspended a related health funding agreement after concerns were filed about the safety of Kenyans' medical information.
Since resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had managed aid for the US government, but Trump claimed its spending was "inefficient" and his government was seeking government-to-government agreements to enhance openness and accountability.
As per statements, Sixteen nations in Africa have so far signed these new health pacts, representing more than $18.3bn in new funding.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently on HIV treatment via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that might be developed from that provided information," his statement read.
"In essence, our country would provide the basic resources for scientific discovery with no assurance that the end products would be available to our population if a future pandemic emerge."
Sovereignty and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were disrupting systems already established through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to manage future pandemics.
"This mechanism is designed to guarantee that when a country provides its data, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," he added.
"We welcome further discussions with our US partners on how subsequent collaboration might be arranged in a way that respects the independence and interests of both nations."
Health Experts Response
Medical experts said it acknowledged the government's concerns, but recommended that negotiations need to persist since a large portion of the country's HIV programmes were funded by international support.
"Where specific concerns exist, such as those relating to data governance or implementation frameworks, these can often be addressed via technical clarification and mutually agreed protections," the group commented.
The situation highlights the ongoing debate between receiving much-needed foreign assistance and safeguarding a country's data in an ever more data-driven world.